Lemtrada
alemtuzumab · Sanofi Belgium
AUTHORISED IN THE EUWhat Lemtrada is used for
Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Lemtrada
- Active substance
- alemtuzumab
- Disease area
- Multiple Sclerosis
- Medicine group
- Selective immunosuppressants
- ATC code
- L04AA34
- Marketing authorisation holder
- Sanofi Belgium
- Authorised in the EU since
- 2013
Official information
In the USA
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lemtrada used for?
Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
What is the active substance in Lemtrada?
Lemtrada contains alemtuzumab.
Who makes Lemtrada?
The EU marketing authorisation holder is Sanofi Belgium.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU